Advent International completes acquisition of Suven Pharmaceuticals

30 Sep 2023 Evaluate

Advent International (Advent) has completed its majority acquisition of Suven Pharmaceuticals (Suven), one of the top contract development and manufacturing organizations (CDMOs) in India.  Advent is also announcing the new Board of Directors and management team for Suven Pharma. 

Advent acquired 50.1% stake in Suven at an agreed price of Rs 495/share. An open offer for the remaining 26% of stake will be triggered within stipulated timelines, and the required details will be announced soon. As a majority stakeholder, Advent plans to foster Suven’s capabilities to help it strive towards becoming one of the leading companies in the CDMO space globally.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.


Suven Pharma Share Price

1072.85 19.90 (1.89%)
08-Apr-2025 10:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1688.75
Dr. Reddys Lab 1108.55
Cipla 1433.45
Lupin 1982.65
Zydus Lifesciences 859.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...